Triple single-pill antihypertensive drug combinations: the key to effective blood pressure control
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Despite the wide selection of antihypertensive medications, blood pressure (BP) control often remains unsatisfactory, and the number of people with uncontrolled hypertension (HTN) increases every year. The aim of this review was to analyze and summarize data from clinical trials and systematic reviews examining the potential of triple singlepill combinations (SPCs) of antihypertensive agents. We focused on amlodipine/indapamide/perindopril combination and its place in the current hypertension treatment strategy. Data are presented demonstrating that triple SPCs represent one of the most effective and safe approaches to hypertension treatment. This SPC of amlodipine/indapamide/perindopril, based on the synergism of complementary mechanisms of action, has one of the most compelling evidence bases among available triple-dose combinations. It can be considered one of the most rational and evidence-based triple therapy options in patients with uncontrolled HTN, particularly those with high cardiovascular risk and the need to rapidly and sustainably achieve target BP levels. Costeffectiveness models have shown that the SPC of amlodipine/indapamide/perindopril can reduce healthcare costs by reducing the incidence of cardiovascular events and hospitalizations while simultaneously increasing life expectancy and quality of life.
Fields of Study & Subjects
Blood Pressure and Hypertension Studies
Sodium Intake and Health
Cardiovascular Health and Disease Prevention
Publication details
- Journal / source
- Russian Journal of Cardiology
- Volume
- 31
- Issue
- 2
- Pages
- 6810–6810
- Publication date
- 29 March 2026
- Language
- EN